Immix Biopharma prices $125 million stock offering alongside NEXICART-2 data update
The company priced 11,363,637 shares at $11.00 each, with the offering expected to close September 30, 2026, as it disclosed new CAR-T trial results.
SEC filing (2)
Latest
Wednesday, September 30
Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post results
Tuesday, September 29
Unicycive resubmits NDA for oxylanthanum carbonate after June 2026 CRL
The company said the new submission adds manufacturing data from a second vendor and expects FDA acceptance within 30 days.
SEC filing
Phathom begins screening in Phase 3 study of as-needed VOQUEZNA for Non-Erosive GERD
The study, pHalcon-NERD-302, could support a label expansion for VOQUEZNA if results are positive, with topline data expected in early 2028.
SEC filing
Lifecore Biomedical agrees to Webster Equity Partners buyout, extends Alcon manufacturing deal to 2034
The deal, valued at up to $663.7 million with milestone payments, follows a September 24 amendment that extends Lifecore's contract manufacturing agreement with Alcon Research through 2034.
SEC filing (2)
Invivyd reports VYD2311 topline safety edge over mRNA COVID vaccine in LIBERTY trial
The Phase 3 LIBERTY study met all primary and secondary endpoints, and Invivyd plans a BLA filing under the Accelerated Approval Program.
SEC filing
Dyne reports new one-year data from ACHIEVE trial of z-basivarsen in DM1
The company disclosed 6- and 12-month results from a pooled dose group and gave the baseline vHOT value for its 71-patient registrational cohort.
SEC filing
HUTCHMED, AstraZeneca file US NDA for Orpathys plus Tagrisso in MET-driven lung cancer
The application, based on the Phase III SAFFRON trial, targets patients who progressed on EGFR-TKI therapy with MET overexpression or amplification.
SEC filing (2)
uniQure reports 48-month AMT-130 data for Huntington's disease gene therapy
The company presented updated Phase I/II results and safety findings on September 29, 2026, ahead of planned BLA and MAA submissions.
SEC filing
Lexeo completes acquisition of Mantle Therapeutics
The merger closed September 29, 2026, with Mantle now a wholly owned subsidiary, as Lexeo's SUNRISE-FA 2 trial continues toward 2H 2027 data.
SEC filing (2)
Tectonic reports Phase 1a safety data for TX2100 in HHT program
The company also disclosed FDA Fast Track designation and IND clearance for TX2100, its APJ receptor antagonist for hereditary hemorrhagic telangiectasia.
SEC filing
Alzamend Neuro discloses MGH lithium imaging data, but 8-K and exhibit name different conferences
The filing's body text cites an ISMRT conference while the attached slides identify an ISMRM workshop, a discrepancy the company did not explain.
SEC filing
Exelixis registers Phase 2 trial pairing zanzalintinib with pembrolizumab in NSCLC
ACADIA's ACP-204 open-label extension study in Lewy body dementia psychosis remains recruiting
NanoViricides extends employment terms for President Diwan and CFO Vyas
The company reported the executive agreement extensions in an 8-K with an earliest-event date of September 28, 2026, signed September 29, 2026.
SEC filing
Larimar Therapeutics names John B. Harlow Jr. president and COO
The board's appointment, effective September 29, 2026, comes with a $560,000 base salary, a $35,000 signing bonus, and inducement equity grants.
SEC filing
Celularity appoints Viome founder Naveen Jain to board of directors
Jain's seat, effective once a Rule 14f-1 waiting period ends, follows board designation rights tied to Celularity's September 2026 financing and comes as director Diane Parks resigns.
SEC filing
Viking Therapeutics registers Phase 1 trial of obesity candidate VK3019
Madrigal registers Phase 4 safety study of Rezdiffra with diabetes drugs in MASH patients
Telix gets FDA Fast Track for BiPASS pre-biopsy prostate imaging program
The designation applies to Telix's 68Ga-PSMA-PET imaging combined with MRI for detecting prostate cancer before biopsy, announced September 30, 2026.
SEC filing
Vetmab Biosciences files Form D for equity offering worth nearly $12 million
The San Diego biotechnology company disclosed it has sold most of an equity offering under Regulation D, with about $505,000 left to sell.
SEC filing
Palisade Bio registers Phase 2 trial of PALI-2108 in ulcerative colitis, recruiting begins
Moleculin closes Part A enrollment in MIRACLE AML trial at 89, one subject still in screening
DBV Technologies submits BLA to FDA for Viaskin Peanut Patch in children 4-7
DBV asked for Priority Review of the application, which is backed by data from the Phase 3 VITESSE trial in 654 children with peanut allergy.
SEC filing
Heron Therapeutics signs multi-product license deal with Long Grove Pharmaceuticals
The Delaware companies entered a Development and License Agreement on September 23, 2026 covering US distribution rights, with terms disclosed in a September 29 SEC filing.
SEC filing
Cadrenal Therapeutics shareholders back share plan increase, warrant issuance at annual meeting
At its September 24, 2026 annual meeting, Cadrenal Therapeutics investors approved a larger equity incentive pool and cleared the way for exercise of warrants tied to a July private placement.
SEC filing
Atossa plans stapled CVR tied to rare pediatric disease review voucher
Atossa Therapeutics said its board approved a plan to give shareholders a contingent value right linked to future proceeds from a priority review voucher, capped at $50 million.
SEC filing
Conexeu Sciences files Form D for $30,875 equity offering
The Nevada-based biotechnology company reported a small stock offering issued as payment for consulting services, with two investors participating.
SEC filing
Altimmune names Richard Menziuso as principal accounting officer
The appointment, effective September 29, 2026, keeps Gregory Weaver as chief financial officer.
SEC filing
GT Biopharma files Form D for offering of up to $38.96 million
The San Francisco biotechnology company has raised $7.75 million so far from nine investors under a Rule 506(b) exemption.
SEC filing
BeyondSpring files $11.9 million at-the-market offering with Citizens
BeyondSpring registered up to 9,200,000 ordinary shares for sale through Citizens JMP Securities under a September 29, 2026 sales agreement, capped by public float rules.
SEC filing
Iovance lifts 2026 revenue guidance to $410-420 million
The company points to strong U.S. uptake of Amtagvi and Proleukin, raising the midpoint by $55 million from its prior range.
SEC filing
Pyxis Oncology terminates $150 million at-the-market stock offering
The company filed a prospectus supplement on September 29, 2026 cutting its ATM sales capacity to zero, though no shares had been sold under the program.
SEC filing
Imunon exchanges part of promissory note for new Series B Preferred Stock
Imunon and Streeterville Capital converted $1.2 million of an existing note into Series B Preferred Shares carrying an 8% annual return.
SEC filing
Evotec's chief scientific officer Cord Dohrmann to step down September 30, 2026
Evotec SE said Dr. Cord Dohrmann will leave his role by mutual consent, with a search underway for his successor.
SEC filing
BrainsWay posts $5.0 million net profit for H1 2026, expands mental health investment portfolio
The company reported higher revenue and profit for the six months ended June 30, 2026, while continuing a series of minority investments in mental health service providers.
SEC filing
Scilex expands Vivasor credit line to $30 million
Scilex Holding Company amended a revolving promissory note with Vivasor, Inc. on September 25, 2026, raising the ceiling from $20 million to $30 million.
SEC filing
Ionis amends REVEAL Phase 3 for obudanersen in Angelman syndrome to two-arm design
FDA panel to meet October 1 on Southern Hemisphere flu vaccine strains
The Vaccines and Related Biological Products Advisory Committee will convene to discuss and recommend strain selections for the 2027 Southern Hemisphere flu season.
FDA
Aquestive Therapeutics adds Rich Daly to board of directors
Daly, former Catalyst Pharmaceuticals CEO, joins effective October 14, 2026, as the company prepares for a potential launch of its allergy drug Anaphylm.
SEC filing
Silexion strikes warrant inducement deal to raise about $0.84 million
The company will lower the exercise price on existing warrants and issue new warrants to holders who agree to exercise, with closing expected September 29, 2026.
SEC filing
Monday, September 28
FDA approves Mirum and Incyte's Atebrioz for FOP; brelovitug hits Phase 3 HDV endpoint
Mirum disclosed FDA approval of Atebrioz for fibrodysplasia ossificans progressiva and positive Phase 3 AZURE-1 results for brelovitug in hepatitis delta, per a September 28, 2026 filing.
SEC filing
Neurocrine names Eiry Roberts chief medical officer, replacing Sanjay Keswani
The Board made the change effective September 28, 2026, after Keswani's departure was agreed on September 25.
SEC filing
Azitra files $3.5 million at-the-market stock offering with A.G.P.
The dermatology biotech, whose shares closed at $0.1680, disclosed a new sales agreement and warned its ATR-12 trial pause and NYSE American price risks could persist.
SEC filing
GlucoTrack amends multiple warrants and notes, removing floor price reduction terms
The company disclosed a series of amendments to bridge, PIPE, and September securities tied to a September 25 registered direct offering repayment.
SEC filing
Gain Therapeutics CFO to resign, CEO to serve as interim finance chief
Gianluca Fuggetta is stepping down as principal financial officer, and Gene Mack will take on the CFO role in addition to his CEO duties starting October 1, 2026.
SEC filing
Azitra sets up $3.5 million at-the-market stock sale facility with A.G.P.
Azitra entered a sales agreement on September 28, 2026 allowing it to sell up to $3,503,232 in common stock through A.G.P./Alliance Global Partners over time.
SEC filing
NeOnc to hold FDA meeting on NEO212 for glioma program
NeOnc Technologies said it will meet with the FDA on November 17, 2026 to discuss Phase 2 design for its brain cancer drug NEO212.
SEC filing